Friday, 4 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentYahoo Finance· March 9, 2026

OSB GROUP PLC - Transaction in Own Shares

View original at finance.yahoo.com
OSB GROUP PLC - Transaction in Own Shares OSB GROUP PLC OSB GROUP PLC ISIN: GB00BLDRH360 9 March 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Share Buyback Programme – Transactions in Own Shares The Company announces that on 06 March 2026 it had purchased a total of 94,482 of its ordinary shares…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

OSB GROUP PLC · highest price paid585.50 GBp_per_share
OSB GROUP PLC · voting rights352568975 voting_shares
OSB GROUP PLC · lowest price paid568.00 GBp_per_share
OSB GROUP PLC · shares repurchased94482 ordinary_shares
OSB GROUP PLC · shares outstanding352568975 ordinary_shares
OSB GROUP PLC · treasury shares0 ordinary_shares
OSB GROUP PLC · vwap575.65 GBp_per_share
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com